Opendata, web and dolomites

HYPMED SIGNED

Digital Hybrid Breast PET/MRI for Enhanced Diagnosis of Breast Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HYPMED" data sheet

The following table provides information about the project.

Coordinator
EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG 

Organization address
address: NEUTORGASSE 9/2
city: WIEN
postcode: 1010
website: www.eibir.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.hypmed.eu
 Total cost 5˙861˙957 €
 EC max contribution 5˙861˙957 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2015-two-stage
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG AT (WIEN) coordinator 394˙637.00
2    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 1˙971˙303.00
3    FUTURA COMPOSITES BV NL (HEERHUGOWAARD) participant 1˙132˙100.00
4    TECHNISCHE UNIVERSITEIT DELFT NL (DELFT) participant 967˙770.00
5    NORAS MRI PRODUCTS GMBH DE (HOCHBERG) participant 595˙875.00
6    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 297˙875.00
7    PHILIPS ELECTRONICS NEDERLAND BV NL (EINDHOVEN) participant 275˙303.00
8    INTRASENSE FR (MONTPELLIER) participant 117˙967.00
9    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 106˙625.00
10    FORSCHUNGSZENTRUM JULICH GMBH DE (JULICH) participant 2˙500.00

Map

 Project objective

Breast cancer represents a leading cause of cancer death in women and a major socio-economic issue. With currently available methods, early diagnosis frequently fails. Moreover, beyond mere detection, there is an ever-increasing need for improved non-invasive characterisation of cancer. Targeted therapies require an in-depth analysis of cancer to select and guide appropriate treatment. Both, PET and MRI can provide molecular and functional information that may be of pivotal importance for tailoring therapy. However, current whole-body PET/MRI systems lack the necessary sensitivity and resolution for this task. HYPMED addresses this by engineering an innovative imaging tool. HYPMED will integrate an innovative fully-digital MRI-transparent PET-detector into a novel multi-channel PET-transparent MRI surface coil. The PET-RF insert will allow unprecedented imaging of breast cancer with high-resolution/ultra-high sensitivity PET, combined with high-level structural and functional MRI, and allow minimal-invasive MR- and PET-guided targeted biopsy. Moreover with such PET-RF inserts, every regular clinical MR-system can, upon demand, be turned into a hybrid system. We will evaluate the impact of this technology on breast cancer diagnosis, prediction, and monitoring/assessment of treatment response by a carefully designed clinical study that employs established and novel PET tracers in 250 patients. Imaging data will be correlated with established and novel molecular biomarkers; results will be compared to those obtained from whole-body PET/MRI and PET/CT. A multidisciplinary consortium of clinical scientists, 3 SMEs and an industry partner will pave the way for commercialization of HYPMED products for advanced clinical decision making in cancer patients. Once HYPMED is successful, we will expand this approach to other applications such as prostate cancer or cardiac hybrid imaging, and thus introduce a paradigm shift in the field of PET/MR hybrid imaging as a whole.

 Deliverables

List of deliverables.
Project Website and CI Websites, patent fillings, videos etc. 2020-04-07 20:24:44

Take a look to the deliverables list in detail:  detailed list of HYPMED deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Michelle Zhang, Joao V. Horvat, Blanca Bernard-Davila, Maria Adele Marino, Doris Leithner, R. Elena Ochoa-Albiztegui, Thomas H. Helbich, Elizabeth A. Morris, Sunitha Thakur, Katja Pinker
Multiparametric MRI model with dynamic contrast-enhanced and diffusion-weighted imaging enables breast cancer diagnosis with high accuracy
published pages: 864-874, ISSN: 1053-1807, DOI: 10.1002/jmri.26285
Journal of Magnetic Resonance Imaging 49/3 2020-04-07
2018 Nicolas Gross-Weege, Thomas Dey, Pierre Gebhardt, David Schug, Bjoern Weissler, Volkmar Schulz
Characterization methods for comprehensive evaluations of shielding materials used in an MRI
published pages: 1415-1424, ISSN: 0094-2405, DOI: 10.1002/mp.12762
Medical Physics 45/4 2020-04-07
2018 Andreas Stadlbauer, Max Zimmermann, Barbara Bennani-Baiti, Thomas H. Helbich, Pascal Baltzer, Paola Clauser, Panagiotis Kapetas, Zsuzsanna Bago-Horvath, Katja Pinker
Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results
published pages: , ISSN: 1536-1632, DOI: 10.1007/s11307-018-1298-4
Molecular Imaging and Biology 2020-04-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPMED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPMED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More